A Comparative Assessment of Mechanisms and Effectiveness of Radiosensitization by Titanium Peroxide and Gold Nanoparticles.
gold nanoparticles
nanoparticles
non-cytotoxic
oxidative stress
radiosensitization
reactive oxygen species
titanium peroxide nanoparticles
Journal
Nanomaterials (Basel, Switzerland)
ISSN: 2079-4991
Titre abrégé: Nanomaterials (Basel)
Pays: Switzerland
ID NLM: 101610216
Informations de publication
Date de publication:
07 Jun 2020
07 Jun 2020
Historique:
received:
03
05
2020
revised:
28
05
2020
accepted:
05
06
2020
entrez:
11
6
2020
pubmed:
11
6
2020
medline:
11
6
2020
Statut:
epublish
Résumé
The development of potentially safe radiosensitizing agents is essential to enhance the treatment outcomes of radioresistant cancers. The titanium peroxide nanoparticle (TiOxNP) was originally produced using the titanium dioxide nanoparticle, and it showed excellent reactive oxygen species (ROS) generation in response to ionizing radiation. Surface coating the TiOxNPs with polyacrylic acid (PAA) showed low toxicity to the living body and excellent radiosensitizing effect on cancer cells. Herein, we evaluated the mechanism of radiosensitization by PAA-TiOxNPs in comparison with gold nanoparticles (AuNPs) which represent high-atomic-number nanoparticles that show a radiosensitizing effect through the emission of secondary electrons. The anticancer effects of both nanoparticles were compared by induction of apoptosis, colony-forming assay, and the inhibition of tumor growth. PAA-TiOxNPs showed a significantly more radiosensitizing effect than that of AuNPs. A comparison of the types and amounts of ROS generated showed that hydrogen peroxide generation by PAA-TiOxNPs was the major factor that contributed to the nanoparticle radiosensitization. Importantly, PAA-TiOxNPs were generally nontoxic to healthy mice and caused no histological abnormalities in the liver, kidney, lung, and heart tissues.
Identifiants
pubmed: 32517328
pii: nano10061125
doi: 10.3390/nano10061125
pmc: PMC7353194
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 16K15581 to R.S., 18K07552 to Hideki Nishimura and R.S.; 19K08121 to H.A.; 18H06179 to H.K.
Références
Int J Nanomedicine. 2018 Nov 23;13:7931-7938
pubmed: 30538469
Adv Drug Deliv Rev. 2011 Mar 18;63(3):136-51
pubmed: 20441782
J Nanobiotechnology. 2004 Apr 30;2(1):3
pubmed: 15119954
Artif Cells Nanomed Biotechnol. 2018;46(sup3):S922-S930
pubmed: 30307330
Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1336-45
pubmed: 11728695
Int J Mol Sci. 2019 Jan 30;20(3):
pubmed: 30704035
Free Radic Biol Med. 1999 Aug;27(3-4):294-300
pubmed: 10468201
Int J Oncol. 2009 Mar;34(3):609-18
pubmed: 19212665
Molecules. 2016 Jun 10;21(6):
pubmed: 27294904
Cancers (Basel). 2016 Feb 25;8(3):
pubmed: 26927177
Biomaterials. 2017 Mar;120:155-184
pubmed: 28063356
Int J Nanomedicine. 2012;7:2673-85
pubmed: 22701316
Int J Radiat Biol. 2017 Mar;93(3):315-323
pubmed: 27690719
Adv Radiat Oncol. 2019 Jan 31;4(2):237-245
pubmed: 31011668
Phys Med Biol. 2004 Sep 21;49(18):N309-15
pubmed: 15509078
Theranostics. 2015 Jun 11;5(9):1030-44
pubmed: 26155318
J Biomed Nanotechnol. 2016 Jan;12(1):165-81
pubmed: 27301182
Lancet Oncol. 2019 Aug;20(8):1148-1159
pubmed: 31296491
Nat Rev Drug Discov. 2009 Jul;8(7):579-91
pubmed: 19478820
Small. 2009 Sep;5(18):2067-76
pubmed: 19642089
Anticancer Res. 2013 May;33(5):1799-807
pubmed: 23645724
Cancer Nanotechnol. 2016;7(1):8
pubmed: 27867425
Int J Nanomedicine. 2020 Jan 31;15:729-734
pubmed: 32099361
Radiother Oncol. 2017 Sep;124(3):344-356
pubmed: 28784439
Langmuir. 2006 Jan 3;22(1):2-5
pubmed: 16378388
Radiat Oncol. 2016 Jul 07;11(1):91
pubmed: 27386977
Curr Drug Targets. 2018;19(14):1696-1709
pubmed: 29577855
Colloids Surf B Biointerfaces. 2008 Oct 15;66(2):274-80
pubmed: 18722754
J Control Release. 2006 Sep 12;114(3):343-7
pubmed: 16876898
Science. 1988 Apr 29;240(4852):640-2
pubmed: 2834821
Int J Mol Sci. 2019 May 15;20(10):
pubmed: 31096608
J Biosci Bioeng. 2018 Jul;126(1):119-125
pubmed: 29428803
Front Pharmacol. 2018 Nov 02;9:1260
pubmed: 30450050
J Biol Chem. 2003 Jan 31;278(5):3170-5
pubmed: 12419811
Oncol Rep. 2008 Jun;19(6):1389-94
pubmed: 18497941
Int J Mol Med. 2003 Dec;12(6):845-50
pubmed: 14612955
Nanotoxicology. 2014 Aug;8(5):521-32
pubmed: 23642008
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):449-54
pubmed: 19735867
Future Oncol. 2012 Sep;8(9):1167-81
pubmed: 23030491
Adv Sci (Weinh). 2019 Jan 08;6(8):1801806
pubmed: 31016110
J Radiat Res. 2005 Sep;46(3):333-41
pubmed: 16210790
Redox Biol. 2016 Dec;10:274-284
pubmed: 27833040
Cancer Nanotechnol. 2017;8(1):2
pubmed: 28217176
Toxicology. 2000 Aug 14;149(1):43-50
pubmed: 10963860
Int J Nanomedicine. 2018 Nov 21;13:7765-7770
pubmed: 30538457
Sci Rep. 2019 Feb 21;9(1):2494
pubmed: 30792478
Clin Cancer Res. 2017 Feb 15;23(4):908-917
pubmed: 27998887
Small. 2008 Jan;4(1):153-9
pubmed: 18081130
Small. 2005 Mar;1(3):325-7
pubmed: 17193451
ACS Nano. 2017 Jul 25;11(7):7164-7176
pubmed: 28640996
Radiat Oncol. 2016 Nov 22;11(1):153
pubmed: 27876069
Colloids Surf B Biointerfaces. 2008 Jun 15;64(1):10-5
pubmed: 18296033
Theranostics. 2016 May 23;6(8):1160-75
pubmed: 27279909
Environ Toxicol Pharmacol. 2015 Mar;39(2):871-8
pubmed: 25791752
Bioconjug Chem. 2004 Jul-Aug;15(4):897-900
pubmed: 15264879
Mol Cancer Ther. 2015 Mar;14(3):788-98
pubmed: 25527634
Free Radic Res. 2016 Dec;50(12):1319-1328
pubmed: 27778515
Int J Toxicol. 2019 Sep/Oct;38(5):357-384
pubmed: 31462100
Radiat Oncol. 2014 Jun 30;9:150
pubmed: 24981953
Nano Lett. 2006 Apr;6(4):662-8
pubmed: 16608261